Objective There are limited data on therapy selection and switching in psoriatic arthritis (PsA). This 18 country, real-world study assessed use and switching of immunomodulatory therapy (biologic/apremilast), the extent of treatment failure and its association with reduced physical functioning, health-related quality of life (HRQoL), and work productivity and activity impairment (WPAI). Methods PsA patients under routine care and their treating physicians provided demographics, current therapy, reasons for switching, duration of first therapy, HRQoL, HAQ-DI, and WPAI. Current immunomodulatory therapy was determined as Bfailing^if, after ≥ 3 months, physician-rated disease severity had worsened, remained severe, was Bunstable/deteriorating,ô r they were dissatisfied with disease control and/or did not consider treatment a Bsuccess.R esults Included were 3714 PsA patients; 1455 (40.6%) had never received immunomodulatory therapy; 1796 (50.1%) had ever received 1 immunomodulatory therapy and 331 (9.2%) ≥ 1. Lack of efficacy with first immunomodulatory therapy was the most common reason for switching; patients whose physicians indicated Bprimary lack of efficacy^as the reason, switched after a mean of 9.4 months. Patients currently failing immunomodulator therapies (n = 246) had poorer HRQoL compared with treatment success (n = 1472) measured by EQ-5D-3L (0.60 vs 0.77%; P < 0.0001); SF-36 PCS (40.8% vs 46.1%; P < 0.0001) MCS (41.1% vs 45.3%; P < 0.0001). Physical functioning, activity, and work productivity were also more impaired (HAQ-DI: 0.88 vs 0.56; activity impairment: 46.7% vs 29.7%; overall work impairment: 35.4% vs 26.1%; all P < 0.0001). Conclusions Poor treatment response in PsA is associated with substantial negative patient impact. In cases of primary treatment failure, timely switching is needed.
Introduction
Psoriatic arthritis (PsA) is a multifaceted systemic chronic inflammatory disease with diverse features, varied outcomes, and disease course, which affects skin and joints simultaneously [1] [2] [3] [4] . The prevalence of psoriatic arthritis (PsA) varies by country, from 0.001% adults in Japan to 0.42% in Italy, and 0.16% in the USA, and is seen in up to 40% of Electronic supplementary material The online version of this article (https://doi.org/10.1007/s10067-019-04446-z) contains supplementary material, which is available to authorized users. psoriasis patients [1] [2] [3] [4] . Patients with PsA experience pain, stiffness, enthesitis, swelling, and tenderness of the joints, with 40-60% of patients developing erosive joint disease leading to impaired articular functioning and higher mortality [1, 2] . These symptoms have a detrimental effect on social relationships, quality of life, and mortality as well as burdening the patient and society with impaired ability to work and substantial healthcare costs [1, 5] .
Conventional disease modifying anti-rheumatic drugs (cDMARDs) including sulfasalazine and methotrexate are widely used in the treatment of PsA [6] . However, advances in understanding PsA pathogenesis, especially the role of T cells and cytokines, have led to a range of immunomodulatory treatments for PsA. The therapeutic armamentarium now also includes biologic DMARDs (bDMARDs) such as tumor necrosis factor inhibitors (TNFis), anti-interleukin (IL)-12/23 ustekinumab, anti-IL-17A secukinumab and ixekizumab, and abatacept. Targeted synthetic DMARDs (tsDMARD) include phosphodiesterase-4 (PDE-4) inhibitor apremilast and janus kinase inhibitor (JAKi) tofacitinib [7] [8] [9] [10] [11] .
The choice of first-line therapy, and which treatment to switch to in the event of first-line treatment failure, is well described in several recent treatment guidelines. The American College of Rheumatology (ACR) and the National Psoriasis Foundation (NPF) most recent guideline for treating PsA recommends TNFi as first-line treatment for active PsA [12] . If a TNFi is not an option, conventional DMARDs (cDMARDs) are preferable to other biologics. Methotrexate is preferable to NSAID, and anti-IL17 is preferable to an IL-12/23 [12] . If PsA is still active after the change, switching to anti-IL-17 should be the next step rather than a cDMARD or other biologic. If PsA continues to be active, switching to an anti-IL12/23 rather than cDMARD, abatacept, or tofacitinib is recommended [12] . The most recent GRAPPA and EULAR recommendations also prefer switching to a bDMARD for patients with active PsA despite cDMARD treatment, usually TNFi, anti-12/23 or anti-IL17 if TNFi is not appropriate, or apremilast if a bDMARD is inappropriate [13, 14] . EULAR recommends switching TNFi if target is not achieved within 3-6 months [14] .
The aim of this large multi-national study was to describe the use of immunomodulatory therapy in PsA patients using real-world data, and assess treatment switching and failure rates, as well as the association between treatment failure and reduced physical functioning, quality of life, and work capability.
Materials and methods

Data source
This was an analysis of data drawn from the Adelphi PsA Disease Specific Program (DSP) conducted between 2015 and 2016 in 18 countries: North America (USA, Canada), Latin America, (LatAm, covering Brazil, Mexico), EU5 (Europe, covering France, Germany, Italy, Spain, UK), Asia Pacific, (APAC, covering Japan, Malaysia, South Korea, Taiwan, Australia), and Turkey & Middle East, (T&ME, covering Egypt, Saudi Arabia, United Arab Emirates) regions [15] . DSPs are large, point-in-time surveys collecting evidence of real-world clinical practice, designed to identify current disease management and patient and physician reported disease impact.
Physicians included in the survey were instructed to complete a pre-specified questionnaire for the next 1-8 (variable by country) consecutive patients with active PsA who visited for routine care. Physician-reported questionnaires included detailed questions on patient demographics, clinical assessments, medication use and treatment history. Each patient with a physician-completed questionnaire was invited to fill out a patient-reported form after providing informed consent. Patients completed their forms independently from physicians, returning them in sealed envelopes to ensure confidentiality.
The Rheumatology DSPs were conducted in accordance with the relevant legislation at time of data collection, including US Health Insurance Portability and Accountability Act 1996 (HIPAA; www.hhs.gov/ocr/privacy/) [16] , and Health Information Technology for Economic and Clinical Health Act legislation [17] . The DSP is a market research project and complies with all relevant market research guidelines and legal obligations. Data were collected according to European Pharmaceutical Marketing Research Association guidelines and thus did not require ethics committee approvals [18] . Namely, the DSP is non-interventional and employs solely retrospective data collection, and no identifiable protected health information was extracted during the course of the study.
Participating physicians and patients
Rheumatologists (and orthopedists and internists in Japan) and dermatologists were eligible to participate if they had worked ≥3 years' as a physician, had qualified between 1979 and 2012, and were responsible for treatment decisions. Rheumatologists were responsible for treatment decisions of axial SpA and PsA patients and dermatologists were responsible for treatment decisions of PsA patients.
Patients were eligible for inclusion if aged ≥ 18 years, with a physician-confirmed diagnosis of PsA, not currently involved in a clinical trial. There were no restrictions according to treatments, clinical features such as disease activity/severity or demographics.
There were no restrictions according to treatments or clinical features such as disease activity/severity or demographics.
Defining Btreatment switchingB
Treatment switching^was defined as progressing from a first immunomodulator therapy to a second therapy of the same or different class. Physicians reported reasons for switching from a list of choices. Reasons for switch included factors associated with lack of initial or ongoing efficacy, failure to control (specific) symptoms, patient change (improvement, worsening), intolerability, issues associated with treatment administration, patient preference, administrative reasons including formulary requirements and physician preference for an alternative therapy. The full list is shown in Supplementary Fig. 1 .
Defining Bfailing^and Bsuccess^treatment groups
Patients were categorized as Bfailing to respond^on current immunomodulatory treatment if, > 3 months after initiating therapy with TNFi, apremilast, or ustekinumab, ≥ 1 of the following criteria, assessed by the treating physician, were met: disease severity (reported as mild, moderate, severe PsA) had worsened or remained severe; disease activity (reported as improving, stable, unstable, deteriorating) was unstable or deteriorating; physicians reported dissatisfaction with current control of PsA; or reported they did not consider the patient's current treatment regimen a Bsuccess^. Any patient not considered in the Bfailing to respond^group was included as a Btreatment success^.
Patient-reported outcomes
Patient-reported forms included validated instruments including the Health Assessment Questionnaire-Disability Index (HAQ-DI) [19] , 5-dimension EuroQoL (EQ-5D-3L) [20] , Medical Outcomes Study Short-Form Health Survey version 2 (SF-36v2) [21] , and the Work Productivity and Activity Impairment (WPAI-GH) [22] questionnaire.
Statistical analyses
Patient characteristics were descriptively analyzed for the total study sample at global and regional levels (North America, LatAm, EU5, APAC, T&ME) by demographics and underlying patient condition (including age, gender, BMI, and BSA affected by psoriasis), number of immunomodulators received, reasons for switching from first to second agent, duration patients remained on first therapy and overall rates of patients failing to respond to immunomodulator therapy and according to line of therapy.
Categorical variables were described by counts and proportions of respondents and continuous numerical variables were described by their medians, means, and standard deviations. Pearson's χ 2 test assessed differences in failure rates by lines of therapy.
Linear regression analyses were performed for EQ 5D, SF-36 PCS and MCS, and WPAI. The independent variable was treatment response (failing to respond or success), and differences in age, gender, BMI, smoking status, time since symptom onset and region were controlled for. Predicted values for all outcomes were subsequently stratified by failure or success while all other variables were fixed at their means.
All analyses used Stata Statistical Software: Release 15 (StataCorp LP, College Station, TX).
Results
Patients and physicians
A total of 949 physicians from 18 countries (North America, n = 155; LatAm, n = 85; EU5, n = 450; APAC, n = 127; T&ME, n = 132) and 3714 PsA patients (North America, n = 707; LatAm, n = 281; EU5, n = 1820; APAC, n = 543; T&ME, n = 363) from the DSP were eligible for inclusion in this analysis; in total 48.2% provided by rheumatologists (including Orthopedic Internal Medicine in Japan), 51.8% by dermatologists.
Key patient demographic and disease characteristics are summarized in Table 1 . Patient characteristics including mean age, BMI, time since diagnosis and HAQ-DI were comparable for most regions with some exceptions. In T&ME, median time since diagnosis and symptom onset was less than other regions at 0.5 year and 1 year compared to 2-3 years and 4-5 years respectively. HAQ-DI was higher for T&ME than for other regions. In addition, there were less patients with mild disease severity and more with moderate disease severity as reported by the treating physician than for other regions. Among patients with psoriasis, those in APAC had the highest proportion of psoriasis affected BSA, with a mean of 13.6% compared to 8.5%-11.3% in other regions.
Of 3714 patients with PsA, 1856 patients completed the voluntary questionnaires, including EQ-5D (n = 1809), SF-36 (n = 1699), and WPAI (n = 1779). Patient reported outcomes were comparable across most regions, other than T&ME where they were notably poorer than other regions.
Use of immunomodulators
Of 3582 patients with complete treatment data, 1455 (40.6%) had never received immunomodulators, 1796 (50.1%) were receiving the first immunomodulator, 243 (6.8%) the second immunomodulator, and 88 (2.5%) the third or later immunomodulator (Table 2 ). Of 2221 globally treated patients (including 94 with incomplete data as to total number of immunomodulators used), the majority received TNFi (84.5%); true across all regions included in this study (Table 2) .
Immunomodulator treatment switching
Supplementary Fig. 1 presents the data for reasons for switching from first to second immunomodulatory therapy. Physicians selected reasons for switching from a prespecified list for 304 PsA patients who had received > 1 immunomodulator and reason for switch was known. Responses that explicitly indicated lack of efficacy were selected for more than two thirds of patients who switched therapy;
Bsecondary lack of efficacy (loss of response over time)ŵ as selected for 134 (44.1%) and Bprimary lack of efficacy (initial non-response)^for 69 (22.7%). Other selected reasons included Bcondition worsened^in 114 (37.5%), Black of pain relief^in 58 (19.1%), Bremission not maintained^in 57 (18.8%) and Bremission was not induced^in 50 (16.4%).
For the 58 whose physicians reported that primary lack of efficacy was the reason for immunomodulator switch, mean duration of initial therapy was 9.4 months (standard deviation 11.9 months) before switching with a maximum time to switch of 84 months (Table 2) .
Immunomodulator treatment response
Based on the definition provided, 246 (14.3%) of patients receiving immunomodulator were currently failing to respond. Rates of current treatment failure increased significantly with successive immunomodulators. Globally, 12.7% of patients currently receiving first therapy were failing current treatment; this doubled to 26.6% for patients currently receiving their third or later therapy (P = 0.0022) (Fig. 1) . In North America and LatAm, rates of failure followed this trend, 11.8% and 14.9% of patients currently failing first therapy increased to 16.7% and 50.0% at third respectively (both P = NS). In Europe and APAC 12.8% and 12.1% of patients on first therapy were reportedly failing which increased to 33.3% (P = 0.0030) and 20.0% (P = NS) failing third respectively. In T&ME, 11.9% patients on first therapy were failing; data are only available for 2 patients who had switched to a second therapy both of whom were failing (Fig. 1) .
Patient demographics by therapy success and failure
Patient characteristics were similar between success and failing groups across all regions with some exceptions in the APAC region; mean BMI was significantly higher (26.1 vs 24.7, P = 0.0309), and time since diagnosis significantly shorter (3.1 vs 5.1, P = 0.0406) for those who were failing therapy (Table 3) . Globally, BSA affected by psoriasis was significantly higher in patients failing therapy (14.5 vs 7.4, P < 0.0001). This pattern was observed for every region apart from APAC (Table 3) . Globally, ESR and CRP levels were significantly higher in patients failing treatment: ESR in North America, EU5, APAC and T&ME; CRP in North America, EU5 and T&ME and numerically higher in the APAC region. ESR and CRP data were too limited in LatAm to be meaningful (Table 3) .
Association of failing treatment with HRQoL and WPAI
Linear regression analysis, controlling for age, gender, smoking status, BMI, time since onset of symptoms and region, confirmed that failing treatment was significantly associated across all regions with lower EQ-5D and HAQ-DI scores ( Fig. 2a and b) ; and worse SF-36 PCS and MCS scores (Fig. 2c) . We also observed that patients who were failing treatment reported significantly worse outcomes on all the individual SF-36 domains (Fig. 3) .
Adjusted WPAI scores were higher in patients failing treatment indicating more work impairment, time missed at work, Patients were deemed to be failing immunomodulator therapy after at least 3 months if disease severity had worsened or remained severe, disease activity was unstable or deteroriating, disease was not considered by physician to be controlled, nor treatment a success. Patients not considered to be failing immunomodulator therapy were considered to be Bimmunomodulator therapy success.^APAC, Asia Pacific region; BMI, body mass index; BSA, body surface area; CRP, c-reactive protein; ESR, erthyrocyte sedimentation rate; EU5, European Union 5; LatAm, Latin America; T & ME, Turkey & Middle East; SD, standard deviation impairment while working and impairment in daily activities than in patients for whom therapy was not failing (Fig. 2d) .
Discussion
This analysis of real-world data on immunomodulator use in patients with PsA from a large multi-national survey demonstrates that current therapies do not consistently deliver sustained efficacy, evidenced by high rates of primary and secondary lack of efficacy to the first treatment (predominantly TNFi), resulting in patients switching therapies, consistent with previous reports [23, 24] . Time to switch therapy due to lack of efficacy may be longer than recommended by EULAR treatment guidelines [6] . In cases where physicians reported switching from first to second immunomodulatory therapy was due to primary lack of efficacy, time to switch to an alternative therapy occurred at a mean of 9.4 months. An observational study based on the nationwide DANBIO registry of 1422 patients with PsA initiating TNFis demonstrated that 39% switched to a second TNFi over a median of 2.3 years follow-up and a US study conducted over 4 years reported 22.9% of patients switched biologic therapy [25] . However, in this global analysis of 3582 patients, at the time of data collection 6.8% had received a second and 2.5% a 3rd therapy, with 9.4% and 4.9% receiving a 2nd and 3rd therapy in the US respectively. These differing rates are a result of our analysis being based on a cross-section of patients with differing disease durations, rather than a longitudinal study of patients over time [26, 27] . East. SF-PCS, P < 0.0001; SF-MCS, P = 0.0010; overall work impairment, P = 0.0727; presenteeism, P = 0.0212; absenteeism, P = 0.3932; activity impairment, P < 0.0001
The likelihood of patients failing their current treatment was higher with each successive therapy. These data are consistent with other studies, including a metanalysis of observational studies published between 2007 and 2015 of patients with PsA who have failed at least one prior TNFi. Compared to patients with no TNFi treatment, TNFi in the second-line and subsequent lines demonstrated statistical improvement in PsA outcomes; however, responses to first-line TNFi demonstrated statistically greater improvements than second-and third-line TNFi. No improvement was found at 24 weeks for fourth-line TNFi compared to second-line treatment [28] . In addition, studies reviewed by Merola et al. indicate that treatment responses and length of treatment survival decrease in patients receiving a second or third TNFi [29] [30] [31] [32] . Recently, large-scale randomized controlled trials of biologics and targeted small molecules demonstrated ACR20/50/ 70 and PASI-75 responses that were significantly improved versus placebo in patients who had failed one or more TNFi [11, [32] [33] [34] . As a result, both updated GRAPPA and EULAR guidelines recommend switching to alternative biologics including those with different modes of action after TNFi failure [13, 14] ; ACR-NPF guidelines specify switching to an anti-IL17 if PsA remains active after failure of a TNFi, followed by an anti-IL12/23 if PsA continues to be active [12] .
The current study was performed before the market authorization of recently approved immunomodulatory agents for PsA; however, the real-world clinical impact of their availability would be expected to impact treatment switching.
Our analyses demonstrate that failure of immunomodulator therapy is associated with significantly poorer patient reported HRQoL by EQ-5D and SF-36, physical functioning by HAQ-DI and performance of daily activities and work by WPAI. We observed that the T&ME cohort had notably worse disease activity and patient reported outcomes compared with other regions. We hypothesize that this may be due to shorter disease duration and lower use of bDMARDs in this region which may have led to poorer disease control compared with other regions.
Although PsA has been reported to negatively impact HRQOL [35] [36] [37] [38] [39] [40] , and several studies report increased absenteeism and presenteeism in patients with PsA [36, [41] [42] [43] to the best of our knowledge, this is the first real-world study to compare HRQoL and work productivity in PsA patients failing treatment, with those whose treatment is considered to working effectively (i.e., not failing).
A major strength of this study is that it presents real-world data from a large number of PsA patients around the world, providing insight into real rates of treatment failure and reasons for treatment switching. Several potential limitations of this Adelphi PsA DSP should be considered. A primary limitation of the analysis is that the source data is a point-in time survey and does not capture the exact timepoint at which patients fail to respond to therapy; therefore, it was necessary to rely on physician-reported reasons for switching therapy to identify the sub-set who failed to respond. Other limitations relate to cross-sectional study design, and selection of patients based on those who agreed to participate. Physician reported disease activity/severity can reflect individual physician bias. Similarly, regional differences in patient characteristics, treatment practices, and physician expertise may have influenced findings in this cross-sectional study. Recall bias is a common limitation of surveys; however, as data was collected at the time of patients' appointments, the likelihood of recall bias is reduced. Finally, although the level of knowledge and management strategies for PsA treatment may differ between rheumatologists and dermatologists, thereby affecting treatment satisfaction and clinical outcomes, differences attributable to physician specialities were not evaluated.
In conclusion, this large multinational real-world survey in PsA patients demonstrated that lack of efficacy of Fig. 3 Spydergram of adjusted SF-36 domain scores for patients failing immunomodulator therapy vs. immunomodulator therapy success. Results are adjusted for age, gender, smoking status, BMI, time since onset of symptoms, and region immunomodulatory therapy was not uncommon and the predominant reason for treatment switching. Failure to respond was associated with significantly poorer patient reported HRQoL, physical functioning, and work productivity. A significant proportion of patients who switched onto second or third therapy did not respond as expected, albeit the majority were TNFis. More regular monitoring and earlier use of appropriate therapies upon identification of lack of efficacy may lead to improvements in disease control and reduce progression leading to improved HRQoL, physical function, and productivity benefits to society.
